Ignite Creation Date:
2024-05-06 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05325632
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2022-03-30
Brief Title:
Study of HER2 Directed Dendritic Cell DC1 Vaccine Weekly Paclitaxel Trastuzumab Pertuzumab
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase II Study of Human Epidermal Growth Factor Receptor 2 HER-2 Directed Dendritic Cell DC1 Vaccine Plus Weekly Paclitaxel Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to find out if an investigational drug called Dendritic Cell DC1 vaccine added to standard neoadjuvant given before main treatment therapy can help people with HER2 human epidermal growth factor receptor 2 positive breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None